Massarweh, Amir Tschernichovsky, Roi Stemmer, Amos Benouaich-Amiel, Alexandra Siegal, Tali Eliakim-Raz, Noa Stemmer, Salomon M. Yust-Katz, Shlomit
Published in
Journal of Neuro-Oncology
Purpose Immunogenicity of Covid-19 vaccines may be negatively impacted by anti-cancer treatment. The management of primary brain tumors (PBTs) routinely includes temozolomide and steroids, which are immune-suppressive. We aimed to determine the rate of seropositivity in PBT patients following receipt of two doses of the BNT162b2 vaccine. Methods We...
Patil, Nirav Somasundaram, Eashwar Waite, Kristin A Lathia, Justin D Machtay, Mitchell Gilbert, Mark R Connor, James R Rubin, Joshua B Berens, Michael E Buerki, Robin A
...
Published in
Journal of neuro-oncology
Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be an important prognostic factor for GBM. The purpose of this study was to develop and independently validate sex-specific nomograms for estimation of individualized GBM survival probabilities using data from 2 independent NRG Oncology clinical trials. This ...
Loizidou, Maria Sefcikova, Viktoria Ekert, Justyna O. Bone, Matan Samandouras, George
Published in
Journal of Neuro-Oncology
Purpose Despite the increasing incidence of currently incurable brain cancer, limited resources are placed in patients’ support systems, with reactive utilisation late in the disease course, when physical and psychological symptoms have peaked. Based on patient-derived data and emphasis on service improvement, this review investigated the structure...
Soler, David C. Kerstetter-Fogle, Amber McCormick, Thomas S. Sloan, Andrew E.
Published in
Journal of Neuro-Oncology
Introduction Glioblastoma multiforme (GBM) constitutes one of the deadliest tumors to afflict humans, although it is still considered an orphan disease. Despite testing multiple new and innovative therapies in ongoing clinical trials, the median survival for this type of malignancy is less than two years after initial diagnosis, regardless of thera...
Barak, Tanyeri Vetsa, Shaurey Nadar, Arushii Jin, Lan Gupte, Trisha P. Fomchenko, Elena I. Miyagishima, Danielle F. Yalcin, Kanat Vasandani, Sagar Gorelick, Evan
...
Published in
Journal of Neuro-Oncology
Yusuf, Mehran Rattani, Abbas Gaskins, Jeremy Oliver, Alexandria L. Mandish, Steven F. Burton, Eric May, Michael E. Williams, Brian Ding, Dale Sharma, Mayur
...
Published in
Journal of Neuro-Oncology
Purpose/Objective(s) To determine, for intact melanoma brain metastases (MBM) treated with single-fraction stereotactic radiosurgery (SRS), whether planning parameter peripheral dose per lesion diameter (PDLDm, Gy/mm) and lesion control (LC) differs with versus without immunotherapy (IO). Materials/Methods We performed a retrospective analysis of p...
Behling, Felix Fodi, Christina Wang, Sophie Hempel, Johann-Martin Hoffmann, Elgin Tabatabai, Ghazaleh Honegger, Jürgen Tatagiba, Marcos Schittenhelm, Jens Skardelly, Marco
...
Published in
Journal of Neuro-Oncology
Introduction Meningiomas are the most common benign intracranial neoplasms. CNS invasion in meningiomas has been integrated into the 2016 WHO classification of CNS tumors as a stand-alone criterion for atypia. Since then, its prognostic impact has been debated based on contradictory results from retrospective analyses. The aim of the study was to e...
Saran, Frank Welsh, Liam James, Allan McBain, Catherine Gattamaneni, Rao Jefferies, Sarah Harris, Fiona Pemberton, Karine Schaible, Jennifer Bender, Shaun
...
Published in
Journal of Neuro-Oncology
Background Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Amplification or overexpression of the epidermal growth factor receptor gene, part of the ErbB family, occur in approximately 40% and 60% of patients with GBM, respectively. We present data from a dose-finding study of the ErbB inhibitor afatinib in...
Winograd, Evan Germano, Isabelle Wen, Patrick Olson, Jeffrey J. Ormond, D. Ryan
Published in
Journal of Neuro-Oncology
Abstract The following questions and recommendations are pertinent to the following: Target population These recommendations apply to adults with progressive GBM who have undergone standard primary treatment with surgery and/or chemoradiation. Question 1 In adults with progressive glioblastoma is the use of bevacizumab as monotherapy superior to st...
Hainc, Nicolin Alsafwani, Noor Gao, Andrew O’Halloran, Philip J. Kongkham, Paul Zadeh, Gelareh Gutierrez, Enrique Shultz, David Krings, Timo Alcaide-Leon, Paula
...
Published in
Journal of Neuro-Oncology
Purpose Differentiation of radiation necrosis from tumor progression in brain metastases treated with stereotactic radiosurgery (SRS) is challenging. For this, we assessed the performance of the centrally restricted diffusion sign. Methods Patients with brain metastases treated with SRS who underwent a subsequent intervention (biopsy/resection) for...